Universal Targeted Immunotherapy (UniTI™) is Elstar’s fully in-house drug discovery platform that underpins a multimodal approach to driving immunological tumor elimination. It is positioned to successfully build a robust pipeline of cancer immunotherapy programs.
Built upon well-understood and validated therapeutic antibody technologies, UniTI™ rapidly generates multi-functional antibody-based biologics that can employ dual-targeting of independent tumor cell surface antigens and recruit multiple innate and adaptive immunological mechanisms to attack diseased cells.
Three key features differentiate UniTI™ molecules:
- dual antigen binding leading to precision targeting to tumor cells,
- modular effector mechanisms engaging selected immune cells, and
- routine, high-yield production processes and excellent drug-like properties.
Elstar’s technology is sufficiently differentiated to overcome barriers that limit others from reaching the full potential of immunotherapeutic drugs.
With UniTI™, the complexity is in the final molecule, not in their design, development, or production.